New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
10:09 EDTZGNX, MSW, X, OMC, GTI, GWAY, SM, NBL, FBR, ACGL, WPPGY, PUBGY, MHP, APAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Apache (APA) downgraded to Hold from Buy at Deutsche Bank... Fibria Celulose (FBR) downgraded to Sell from Neutral at Citigroup... GrafTech (GTI) downgraded to Hold from Buy at Jefferies... McGraw-Hill (MHP) downgraded to Neutral from Buy at Lazard Capital... Noble Energy (NBL) downgraded to Neutral from Buy at Sterne Agee... Omnicom (OMC) downgraded to Hold from Buy at Deutsche Bank... Publicis (PUBGY) downgraded to Sell from Hold at Deutsche Bank... SM Energy (SM) downgraded to Hold from Buy at Deutsche Bank... U.S. Steel (X) downgraded to Underperform from Neutral at Longbow... WPP PLC (WPPGY) downgraded to Hold from Buy at Deutsche Bank... Greenway Medical (GWAY) downgraded to Underperform from Neutral at Sterne Agee... Corcept Therapeutics (MHP) downgraded to Neutral from Outperform at Cowen... Arch Capital (ACGL) downgraded to Hold from Buy at Stifel Nicolaus.. Mission West Properties (MSW) downgraded to Hold from Buy at Stifel Nicolaus... Zogenix (ZGNX) downgraded to Hold from Buy at Stifel Nicolaus.
News For APA;FBR;GTI;MHP;NBL;OMC;PUBGY;SM;X;WPPGY;GWAY;MSW;ACGL;ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
14:04 EDTGTIGabelli reports 6.96% stake in GrafTech
Subscribe for More Information
10:52 EDTACGLBofA/Merrill non-life insurance analysts hold analyst/industry conference call
Subscribe for More Information
May 27, 2015
08:44 EDTZGNXZogenix announces new efficacy data from study of low-dose fenfluramine
Zogenix announced new data demonstrating sustained efficacy and tolerability for patients treated with low-dose fenfluramine as an adjunctive therapy for Dravet syndrome. The data was authored by world-renown experts in the field of Dravet syndrome, Berten Ceulemans, M.D., Ph.D. and Lieven Lagae, M.D., Ph.D., from the Universities of Antwerp and Leuven in Belgium, and was presented at the European Paediatric Neurology Society meeting taking place this week in Vienna, Austria. Zogenix intends to initiate Phase 3 clinical studies for ZX008, the company's investigational proprietary pediatric formulation of low-dose fenfluramine, during the second half of 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome. The results presented are from the latest 5-year follow-up period in a group of Dravet syndrome patients being treated with low-dose fenfluramine. This analysis, which includes ten patients from the original study group and two patients who began treatment in 2011, demonstrated that during any given year of the follow-up period, at least 80% of patients achieved a greater than or equal to 75% reduction in the frequency of seizures. In addition, three patients were seizure-free for all 5 years and five patients were seizure-free for 2 to 4 years. The use of low-dose fenfluramine in this group of patients was shown to be generally well tolerated, with the most common adverse events being transient loss of appetite and fatigue/somnolence. No clinically meaningful cardiac adverse events were noted. No patient discontinued treatment due to adverse events. In addition, a recently published translational research study to elucidate fenfluramine's mechanism of action in Dravet syndrome demonstrated the ability of fenfluramine to significantly reduce locomotion and eliminate epileptiform EEG activity in a gene knockdown zebrafish model of Dravet syndrome. These data support the clinical results obtained in the Belgium cohort of patients.
May 21, 2015
07:25 EDTSMUBS to hold a conference
Subscribe for More Information
May 20, 2015
07:26 EDTNBLUBS to hold a conference
Subscribe for More Information
May 19, 2015
09:45 EDTNBLNoble Energy upgraded to Buy from Neutral at Global Hunter
07:44 EDTNBLCowen sees energy M&A focusing on accretive deals from non-core assets
Subscribe for More Information
07:31 EDTAPAUBS to hold a conference
Subscribe for More Information
May 18, 2015
15:29 EDTGTIOptions with increasing volume
Options with increasing volume: ACHN PAGP CBG NI NGLS LEA OKS GTI WETF URBN
13:20 EDTACGLArch has made multiple AXIS Capital approaches, The Insurance Insider reports
Subscribe for More Information
10:10 EDTGTIHigh option volume stocks
High option volume stocks: ASNA LAZ GTI CBRL ANN ISSI ANET HTS URBN LVLT
09:49 EDTGTIEquity options with increasing volume
Subscribe for More Information
08:05 EDTGTIGrafTech announces agreement, plan of merger with Brookfield affiliate
Subscribe for More Information
May 15, 2015
17:33 EDTNBLPoint72 Asset Management gives quarterly update on stakes
Subscribe for More Information
17:08 EDTNBLSoros Fund gives quarterly update on stakes
Subscribe for More Information
16:21 EDTNBLStocks end week little changed as data, deals offset bond yield jumps
Stocks ended the week little changed as a number of M&A deals and a few relatively strong economic data points offset worries about rising bond yields. MACRO NEWS: U.S. weekly jobless claims came in better than expected and reached the lowest four-week average level in 15 years... In Europe, the combined GDP of the 19 eurozone countries grew 0.4% in the first quarter, which was a bit weaker than the 0.5% consensus growth forecast but a pickup from the 0.3% growth pace of the final quarter of last year. Of note, all four of the euro zone's largest economies recorded growth in the same quarter for the first time since the first half of 2010... The People's Bank of China reduced its one year interest rate by 0.25%, marking the third time in the last six months that the central bank has cut benchmark rates... Bond yields surged in many of the world's largest economies, raising worries about inflation and putting pressure on stocks in the beginning of the week. COMPANY NEWS: There was a significant amount of M&A activity again this week, with the headliner being Verizon's (VZ) deal to acquire AOL (AOL) for $50 per share in a transaction valued at $4.4B. Danaher (DHR) agreed to buy purification technologies supplier Pall Corporation (PLL) for $127.20 per share in cash. Danaher also announced that it plans to split itself into two publicly traded companies. Energy infrastructure company Williams (WMB) announced a simplification deal to buy its affiliate Williams Partners (WPZ) for $13.9B in an all-stock transaction. Energy exploration company Noble Energy (NBL) agreed to acquire Rosetta Resources (ROSE) in an all-stock deal. Noble is buying Rosetta for $2.1B in stock plus the assumption of Rosetta's net debt of $1.8B... Alibaba (BABA) acquired a 9.3% stake in Zulily (ZU), an e-commerce retailer geared toward women. A person familiar with the matter reportedly told the Wall Street Journal that the Chinese e-commerce giant is not pursuing an outright acquisition of the U.S. company, however... Shares of Netflix (NFLX) jumped Friday and hit a new all-time high after Bloomberg reported that the company is in talks with Wasu Media, a Chinese media company backed by Alibaba Executive Chairman Jack Ma, about forming a partnership to bring its content to China... Nelson Peltz's Trian Fund Management lost its proxy fight with DuPont (DD) as Trian did not succeed in getting its nominees elected to the DuPont board. INDEXES: For the week, the Dow rose 0.45% to 18,272.56, the Nasdaq gained 0.89% to 5,048.29, and the S&P 500 climbed 0.31% to 2,122.73.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use